Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines

Nature Reviews Cancer

Volumn 8, Issue 5, 2008, Pages 351-360

  Melief, Cornelis J M ^a   Van Der Burg, Sjoerd H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE; DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MALARIA VACCINE; PEPTIDE VACCINE; T LYMPHOCYTE ANTIBODY; TUMOR ANTIGEN; VIRUS ANTIGEN; VIRUS VACCINE; WART VIRUS VACCINE;

AMINO ACID SEQUENCE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CLINICAL TRIAL; DRUG BINDING; DRUG MECHANISM; HELPER CELL; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; MALARIA; NONHUMAN; PRECANCER; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; UTERINE CERVIX CANCER; WART VIRUS;

ANIMALS; CANCER VACCINES; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY, ACTIVE; MICE; PEPTIDES; PRECANCEROUS CONDITIONS; RABBITS; VACCINES, SUBUNIT;

EID: 42549138499     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2373     Document Type: Review

References (117)

1. Rosenberg, S. A. & Dudley, M. E. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc. Natl Acad. Sci. USA 101 (Suppl. 2), 14639-14645 (2004).
2. Cavallo, F., Offringa, R., van der Burg, S. H., Forni, G. & Melief, C. J. Vaccination for treatment and prevention of cancer in animal models. Adv. Immunol. 90, 175-213 (2006).
3. Bijker, M. S., Melief, C. J., Offringa, R. & van der Burg, S. H. Design and development of synthetic peptide vaccines: past, present and future. Expert Rev. Vaccines 6, 591-603 (2007).
4. van der Burg, S. H., Bijker, M. S., Welters, M. J., Offringa, R. & Melief, C. J. Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy. Adv. Drug Deliv. Rev. 58, 916-930 (2006).
5. Schuurhuis, D. H. et al. Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. J. Immunol. 176, 4573-4580 (2006).
6. Zwaveling, S. et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol. 169, 350-358 (2002). The first head-to-head comparison in mice between minimal MHC class I binding peptide vaccine and a long peptide vaccine, showing that the latter induces an effective anti-tumour response with the capacity to eradicate established tumours in mice.
7. Vambutas, A. et al. Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. Vaccine 23, 5271-5280 (2005). This paper shows that an immune response induced by vaccination with a pool of long peptides is able to eradicate established virus-induced premalignant epithelial lesions growing in their natural context in rabbits.
8. Melief, C. J. et al. Long peptide vaccine-induced migration of HPV16-specific type 1 and 2 T cells into the lesions of VIN III patients associated with complete clinical responses. Cancer Immun. 7, 20 (2007).
9. Kenter, G. et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high risk HPV16 in end stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin. Cancer Res. 14, 169-177 (2008).
10. + T-cell immunity in cervical cancer patients by an HPV16 E6 and E7 long-peptide vaccine. Clin. Cancer Res. 14, 178-187 (2008). References 9 and 10 show that the concept of vaccination with a set of long overlapping peptides spanning the full length of the two oncogenic proteins E6 and E7 of high-risk HPV16 successfully induces robust E6/E7-specific T-cell responses to multiple CD4 and CD8 epitopes of HPV16 E6 and E7 in patients with cervical cancer.
11. Harrop, R., John, J. & Carroll, M. W. Recombinant viral vectors: cancer vaccines. Adv. Drug Deliv. Rev. 58, 931-947 (2006).
12. Schlom, J., Arlen, P. M. & Gulley, J. L. Cancer vaccines: moving beyond current paradigms. Clin. Cancer Res. 13, 3776-3782 (2007).
13. Kanodia, S., Da Silva, D. M. & Kast, W. M. Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int. J. Cancer 122, 247-259 (2008).
14. Gudmundsdotter, L. et al. Therapeutic immunization for HIV. Springer Semin. Immunopathol. 28, 221-230 (2006).
15. Pol, S. & Michel, M. L. Therapeutic vaccination in chronic hepatitis B virus carriers. Expert Rev. Vaccines 5, 707-716 (2006).
16. Figdor, C. G., de Vries, I. J., Lesterhuis, W. J. & Melief, C. J. Dendritic cell immunotherapy: mapping the way. Nature Med. 10, 475-480 (2004).
17. Gilboa, E. DC-based cancer vaccines. J. Clin. Invest. 117, 1195-1203 (2007).
18. Tacken, P. J., de Vries, I. J., Torensma, R. & Figdor, C. G. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nature Rev. Immunol. 7, 790-802 (2007).
19. Ueno, H. et al. Dendritic cell subsets in health and disease. Immunol. Rev. 219, 118-142 (2007).
20. Tsen, S. W., Paik, A. H., Hung., C. F. & Wu, T. C. Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Expert Rev. Vaccines 6, 227-239 (2007).
21. Rice, J., Ottensmeier, C. H. & Stevenson, F. K. DNA vaccines: precision tools for activating effective immunity against cancer. Nature Rev. Cancer 8, 108-120 (2008).
22. Corradin, G., Spertini, F. & Verdini, A. Medicinal application of long synthetic peptide technology. Expert Opin. Biol. Ther. 4, 1629-1639 (2004).
23. Moudgil, K. D. & Sercarz, E. E. Dominant determinants in hen eggwhite lysozyme correspond to the cryptic determinants within its self-homologue, mouse lysozyme: implications in shaping of the T cell repertoire and autoimmunity. J. Exp. Med. 178, 2131-2138 (1993).
24. Pickup, D. J. Understanding orthopoxvirus interference with host immune responses to inform novel vaccine design. Expert Rev. Vaccines 6, 87-95 (2007).
25. Smith, G. L., Symons, J. A., Khanna, A., Vanderplasschen, A. & Alcami, A. Vaccinia virus immune evasion. Immunol. Rev. 159, 137-154 (1997).
26. Aichele, P., Hengartner, H., Zinkernagel, R. M. & Schulz, M. Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide. J. Exp. Med. 171, 1815-1820 (1990).
27. 53 it was reported that the peptide that was used also contained a helper T-cell epitope.
28. Knutson, K. L. & Disis, M. L. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol. Immunother. 54, 721-728 (2005).
29. Kast, W. M. et al. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc. Natl. Acad. Sci. USA 88, 2283-2287 (1991).
30. Feltkamp, M. C. et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16- transformed cells. Eur. J. Immunol. 23, 2242-2249 (1993). First report on the use of a successful peptide vaccine that was able to prevent the outgrowth of transplanted tumour cells in mice.
31. + T cells. Proc. Natl Acad. Sci. USA 91, 3171-3175 (1994).
32. Mandelboim, O. et al. Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nature Med. 1, 1179-1183 (1995).
33. Toes, R. E., Blom, R. J., Offringa, R., Kast, W. M. & Melief, C. J. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J. Immunol. 156, 3911-3918 (1996).
34. Toes, R. E., Offringa, R., Blom, R. J., Melief, C. J. & Kast, W. M. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl Acad. Sci. USA 93, 7855-7860 (1996).
35. Bijker, M. S. et al. CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J. Immunol. 179, 5033-5040 (2007). This paper shows that the injection of vaccines consisting of highly immunogenic minimal MHC class I binding peptide vaccines mixed with IFA results in a transient effector Tc response but fails to induce Tc memory in mice.
36. Toes, R. E. et al. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J. Immunol. 160, 4449-4456 (1998).
37. Bijker, M. S. et al. Superior induction of anti-tumour CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur. J. Immunol. 38, 1-10 (2008). A mouse study demonstrating that in vivo long peptides are preferentially presented by professional APCs whereas minimal peptides are also presented by B cells and T cells. B-cell-knockout mice reveal that B cells have a key role in the priming of T cells when minimal peptides but not when long peptides are used.
38. Melief, C. J. M. et al. Strategies for immunotherapy of cancer. Adv. Immunol. 75, 235 - 281 (2000).
39. Heath, W. R. & Carbone, F. R. Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. 19, 47-64 (2001).
40. Chen, W., Yewdell, J. W., Levine, R. L. & Bennink, J. R. Modification of cysteine residues in vitro and in vivo affects the immunogenicity and antigenicity of major histocompatibility complex class I-restricted viral determinants. J. Exp. Med. 189, 1757-1764 (1999).
41. Feltkamp, M. C., Vierboom, M. P., Kast, W. M. & Melief, C. J. Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity. Mol. Immunol. 31, 1391-1401 (1994).
42. van der Burg, S. H., Visseren, M. J., Brandt, R. M., Kast, W. M. & Melief, C. J. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J. Immunol. 156, 3308-3314 (1996).
43. Valmori, D. et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol. 160, 1750-1758 (1998).
44. Tsuboi, A. et al. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A* 2402-binding residues. Cancer Immunol. Immunother. 51, 614-620 (2002).
45. Sette, A. et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153, 5586-5592 (1994).
46. + T cells with enhanced functional characteristics: implication for more effective immunotherapy. Cancer Res. 59, 301-306 (1999).
47. Lee, P. et al. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J. Clin. Oncol. 19, 3836-3847 (2001).
48. Dyall, R. et al. Heteroclitic immunization induces tumor immunity. J. Exp. Med. 188, 1553-1561 (1998).
49. Lienard, D. et al. Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun. 4, 4 (2004).
50. Weber, J. Peptide vaccines for cancer. Cancer Invest. 20, 208-221 (2002).
51. Wang, F. et al. On defining the rules for interactions between the T cell receptor and its ligand: a critical role for a specific amino acid residue of the T cell receptor β chain. Proc. Natl Acad. Sci. USA 95, 5217-5222 (1998).
52. + cytotoxic lymphocyte population. J. Immunol. 162, 7263-7270 (1999).
53. + T cell help. J. Immunol. 147, 4069-4073 (1991).
54. Bennett, S. R. M. et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393, 478-480 (1998).
55. Schoenberger, S. P., Toes, R. E., van der Voort, E. I., Offringa, R. & Melief, C. J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393, 480-483 (1998).
56. + cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli. J. Exp. Med. 192, 145-150 (2000).
57. Valmori, D. et al. Induction of a cytotoxic T cell response by co-injection of a T helper peptide and a cytotoxic T lymphocyte peptide in incomplete Freund's adjuvant (IFA): further enhancement by pre-injection of IFA alone. Eur. J. Immunol. 24, 1458-1462 (1994).
58. Widmann, C., Romero, P., Maryanski, J. L., Corradin, G. & Valmori, D. T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides. J. Immunol. Methods 155, 95-99 (1992).
59. Scheibenbogen, C. et al. Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides. Int. J. Cancer 104, 188-194 (2003).
60. Ossendorp, F., Mengede, E., Camps, M., Filius, R. & Melief, C. J. M. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp.Med. 187, 1-10 (1998).
61. Casares, N. et al. Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity. Eur. J. Immunol. 31, 1780-1789 (2001).
62. + T helper cells. J. Virol. 75, 10593-10602 (2001).
63. Hossain, A., Zheng, C. L., Kukita, A. & Kohashi, O. Balance of Th1/Th2 cytokines associated with the preventive effect of incomplete Freund's adjuvant on the development of adjuvant arthritis in LEW rats. J. Autoimmun. 17, 289-295 (2001).
64. Shibaki, A. & Katz, S. I. Induction of skewed Th1/Th2 T-cell differentiation via subcutaneous immunization with Freund's adjuvant. Exp. Dermatol. 11, 126-134 (2002).
65. Gerard, C. M. et al. Therapeutic potential of protein and adjuvant vaccinations on tumour growth. Vaccine 19, 2583-2589 (2001).
66. + cytotoxic T lymphocytes. Int. Immunol. 16, 55-63 (2004).
67. Schwarz, K. et al. Role of Toll-like receptors in costimulating cytotoxic T cell responses. Eur. J. Immunol. 33, 1465-1470 (2003).
68. + T cell expansion with variable dependence on type I IFN. J. Exp. Med. 199, 775-784 (2004).
69. + T cell responses. J. Immunol. 174, 7676-7683 (2005).
70. Rechtsteiner, G., Warger, T., Osterloh, P., Schild, H. & Radsak, M. P. Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod. J. Immunol. 174, 2476-2480 (2005).
71. Welters, M. J. et al. Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists. Vaccine 25, 1379-1389 (2007).
72. + T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells. Eur. J. Immunol. 32, 731-741 (2002).
73. Monsurro, V. et al. Active-specific immunization against melanoma: is the problem at the receiving end? Semin. Cancer Biol. 13, 473-480 (2003).
74. + T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115, 739-746 (2005).
75. Diehl, L. et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nature Med. 5, 774-779 (1999).
76. den Boer, A. T. et al. Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance. J. Immunol. 167, 2522-2528 (2001).
77. Napolitani, G., Rinaldi, A., Bertoni, F., Sallusto, F. & Lanzavecchia, A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nature Immunol. 6, 769-776 (2005).
78. + CTL in vivo with peptide vaccine constructs. J. Immunol. 152, 549-556 (1994). This mouse study not only shows that the inclusion of helper T cell epitopes in minimal MHC class I binding peptide vaccines results in a stronger Tc response but also that the strongest responses are obtained when the helper T-cell peptide and Tc peptide are physically linked.
79. Hiranuma, K. et al. Helper T cell determinant peptide contributes to induction of cellular immune responses by peptide vaccines against hepatitis C virus. J. Gen. Virol. 80, 187-193 (1999).
80. Maurer, T. et al. CpG-DNA aided cross-presentation of soluble antigens by dendritic cells. Eur. J. Immunol. 32, 2356-2364 (2002).
81. Khan, S. et al. Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells. J. Biol. Chem. 282, 21145-21159 (2007).
82. Jackson, D. C. et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc. Natl Acad. Sci. USA 101, 15440-15445 (2004). A mouse study showing that completely synthetic vaccines composed of a TLR ligand, a helper T-cell epitope and a Tc epitope protect against viral infections and mediate prophylactic and therapeutic activity against tumours.
83. Tighe, H. et al. Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur. J. Immunol. 30, 1939-1947 (2000).
84. Borges, E., Wiesmuller, K. H., Jung, G. & Walden, P. Efficacy of synthetic vaccines in the induction of cytotoxic T lymphocytes. Comparison of the costimulating support provided by helper T cells and lipoamino acid. J. Immunol. Methods 173, 253-263 (1994).
85. Deres, K., Schild, H., Wiesmuller, K. H., Jung, G. & Rammensee, H. G. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 342, 561-564 (1989).
86. Heit, A. et al. Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines. J. Immunol. 174, 4373-4380 (2005).
87. Roth, A. et al. Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct. Br. J. Cancer 92, 1421-1429 (2005).
88. Daftarian, P. et al. Novel conjugates of epitope fusion peptides with CpG-ODN display enhanced immunogenicity and HIV recognition. Vaccine 23, 3453-3468 (2005).
89. Kast, W. M., Brandt, R. M. & Melief, C. J. Strict peptide length is not required for the induction of cytotoxic T lymphocyte-mediated antiviral protection by peptide vaccination. Eur. J. Immunol. 23, 1189-1192 (1993).
90. Gao, X. M., Zheng, B., Liew, F. Y., Brett, S. & Tite, J. Priming of influenza virus-specific cytotoxic T lymphocytes vivo by short synthetic peptides. J. Immunol. 147, 3268-3273 (1991).
91. + T-cell responses and prolongs survival of thymoma-bearing mice. Cancer Res. 54, 4155-4161 (1994).
92. Reinholdsson-Ljunggren, G., Ramqvist, T., Ahrlund-Richter, L. & Dalianis, T. Immunization against polyoma tumors with synthetic peptides derived from the sequences of middle- and large-T antigens. Int. J. Cancer 50, 142-146 (1992).
93. Falo, L. D. Jr, Colarusso, L. J., Benacerraf, B. & Rock, K. L. Serum proteases alter the antigenicity of peptides presented by class I major histocompatibility complex molecules. Proc. Natl Acad. Sci. USA 89, 8347-8350 (1992).
94. Amoscato, A. A., Prenovitz, D. A. & Lotze, M. T. Rapid extracellular degradation of synthetic class I peptides by human dendritic cells. J. Immunol. 161, 4023-4032 (1998).
95. Larsen, S. L., Pedersen, L. O., Buus, S. & Stryhn, A. T cell responses affected by aminopeptidase N. (CD13)-mediated trimming of major histocompatibility complex class II-bound peptides. J. Exp. Med. 184, 183-189 (1996).
96. + T cells. J. Exp. Med. 188, 1977-1983 (1998).
97. Suhrbier, A. et al. Peptide epitope induced apoptosis of human cytotoxic T lymphocytes. Implications for peripheral T cell deletion and peptide vaccination. J. Immunol. 150, 2169-2178 (1993).
98. + cytotoxic T lymphocytes is due to fratricide. J. Immunol. 151, 658-667 (1993).
99. Lefrancois, L., Marzo, A. & Williams, K. Sustained response initiation is required for T cell clonal expansion but not for effector or memory development in vivo. J. Immunol. 171, 2832-2839 (2003).
100. Obst, R. et al. Sustained antigen presentation can promote an immunogenic T cell response, like dendritic cell activation. Proc. Natl Acad. Sci. USA 104, 15460-15465 (2007).
101. Tindle, R. W., Fernando, G. J. P., Sterling, J. C. & Frazer, I. H. A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. Proc. Natl. Acad. Sci. USA 88, 5887-5591 (1991).
102. Takahashi, H., Germain, R. N., Moss, B. & Berzofsky, J. A. An immunodominant class I-restricted cytotoxic T lymphocyte determinant of human immunodeficiency virus type 1 induces CD4 class II-restricted help for itself. J. Exp. Med. 171, 571-576 (1990).
103. + T-cell clones from congenital rubella syndrome patients with IDDM recognize overlapping GAD65 protein epitopes. Implications for HLA class I and II allelic linkage to disease susceptibility. Hum. Immunol. 60, 652-664 (1999).
104. + T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res. 62, 3630-3635 (2002).
105. Knutson, K. L., Schiffman, K. & Disis, M. L. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J. Clin. Invest. 107, 477-484 (2001).
106. + T lymphocyte immune response in humans. Implications for vaccination strategies. Eur. J. Immunol. 31, 1989-1998 (2001).
107. + T-helper response against the p53 tumor antigen. Cancer Res. 68, 893-900 (2008).
108. + T-helper cells. Cancer Res. 62, 6187-6193 (2002).
109. Offringa, R., van der Burg, S. H., Ossendorp, F., Toes, R. E. & Melief, C. J. Design and evaluation of antigen-specific vaccination strategies against cancer. Curr. Opin. Immunol. 12, 576-582 (2000).
110. + lines propagated with tetanus toxoid or with synthetic tetanus toxin sequences. J. Autoimmun. 9, 79-88 (1996).
111. Nowak, A. K., Lake, R. A. & Robinson, B. W. Combined chemoimmunotherapy of solid tumours: improving vaccines? Adv. Drug Deliv. Rev. 58, 975-990 (2006).
112. Bae, S. H. et al. Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy. Clin. Cancer Res. 13, 341-349 (2007).
113. Disis, M. L. et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J. Clin. Oncol. 20, 2624-2632 (2002).
114. Audran, R. et al. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect. Immun. 73, 8017-8026 (2005).
115. Villard, V. et al. Rapid identification of malaria vaccine candidates based on alpha-helical coiled coil protein motif. PLoS ONE 2, e645 (2007). The studies reported in references 114 and 115 showed the capacity of long synthetic peptide vaccines against malaria to induce strong specific T-cell responses as well as neutralizing cross-reactive antibodies.
116. Nijman, H. W. et al. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur. J. Immunol. 23, 1215-1219 (1993).
117. De Bruijn, M. L. et al. Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses. Eur. J. Immunol. 21, 2963-2970 (1991).